$ACON

Ness Brent purchased $12K of ACON

Ness Brent (Chief Executive Officer) purchased 5,234 shares of Aclarion, Inc. (ACON) at $2.31 on 2026-08-13.

Original reporting
SEC EDGAR · Ness Brent
Published Aug 17, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 1:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ACON
Bullish
medium confidence
Mentioned
$ACON
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACONBullishLow
01

Why it matters

The newest disclosed fact is the CEO’s open-market purchase details (shares, price, total value) and post-transaction holdings.

02

Market read

Traders may note the insider buy as a mild positive sentiment datapoint, but the disclosure does not include guidance, contracts, or other fundamental catalysts.

03

What to watch

The purchase is small in dollar terms and explicitly not under a pre-arranged 10b5-1 plan, which can make the signal noisier rather than cleaner.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-17, transaction dated 2026-08-13

Background

The article is a SEC Form 4 insider transaction disclosure for Aclarion, Inc. (ACON).

Company-level read

Ticker impact

$ACONBullishMedium confidence
Context

Aclarion CEO Ness Brent filed a Form 4 for an open-market purchase of 5,234 shares at $2.31 on 2026-08-13.

Expected impact

Low near-term impact; any effect is likely sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 insider buys can support bullish sentiment, but the disclosed size ($12.1k) and lack of a 10b5-1 plan reduce the likelihood of a durable, information-rich signal.

Market effects

No sector-level implications; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be routine liquidity or diversification activity and may not reflect a material change in fundamentals.

Key entities

  • Aclarion, Inc.

    Company whose CEO insider transaction is disclosed on Form 4.

  • Ness Brent

    CEO and director who purchased shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACONMed

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI

Aclarion (Nasdaq: ACON) said it launched a U.S. Market Access Program with PRIA Healthcare to advance reimbursement and commercial adoption of its AI platform Nociscan for chronic low back pain. PRIA will support payer engagement, prior authorization and appeals. Aclarion cited UK payer approvals from three of four major private insurers as a basis for U.S. coverage discussions.

$ACONMedAI 8/10

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Aclarion (Nasdaq: ACON) said it has agreed with the Institute of Neuro Innovation in Los Angeles to expand availability of its Nociscan platform. The INI team led by neurosurgeon Amir Vokshoor will generate real-world evidence comparing Nociscan’s lumbar disc chemical biomarker data with bone metabolic information from SPECT-CT to support treatment decisions for chronic low back pain.